31R Stock Overview
A life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Revive Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.029 |
| 52 Week Low | CA$0.0005 |
| Beta | -0.29 |
| 11 Month Change | 0% |
| 3 Month Change | -93.75% |
| 1 Year Change | -94.19% |
| 33 Year Change | -99.86% |
| 5 Year Change | -96.43% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 31R | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -95.5% | -1.0% | 0.2% |
| 1Y | -94.2% | -19.3% | 8.5% |
Return vs Industry: 31R underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 31R underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 31R volatility | |
|---|---|
| 31R Average Weekly Movement | 1,068.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 31R's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 31R's weekly volatility has increased from 939% to 1069% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Michael Frank | revivethera.com |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.
Revive Therapeutics Ltd. Fundamentals Summary
| 31R fundamental statistics | |
|---|---|
| Market cap | €2.88m |
| Earnings (TTM) | -€3.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 31R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 31R income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$5.62m |
| Earnings | -CA$5.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 31R perform over the long term?
See historical performance and comparison